FGF21 response to critical illness: Effect of blood glucose control and relation with cellular stress and survival

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 10, 2015, Pages E1319-E1327

  Thiessen, Steven E ^a   Vanhorebeek, Ilse ^a   Derese, Inge ^a   Gunst, Jan ^a   Van Den Berghe, Greet ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; INSULIN; SOMATOMEDIN C; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; CRITICAL ILLNESS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; FGF21 GENE; GENE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN RESISTANCE; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RABBIT MODEL; SURVIVAL RATE; ANIMAL; BLOOD; DISEASE MODEL; INTENSIVE CARE UNIT; LIVER; METABOLISM; MIDDLE AGED; MITOCHONDRION; MORTALITY; OXIDATIVE STRESS; PHYSIOLOGY; RABBIT; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; BLOOD GLUCOSE; CRITICAL ILLNESS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERGLYCEMIA; INSULIN; INTENSIVE CARE UNITS; LIVER; MALE; MIDDLE AGED; MITOCHONDRIA; OXIDATIVE STRESS; RABBITS;

EID: 84943740629     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2700     Document Type: Article

References (40)

1. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978-982.
2. Whitcomb BW, Pradhan EK, Pittas AG, Roghmann MC, Perencevich EN. Impact of admission hyperglycemia on hospital mortality in various intensive care unit populations. Crit Care Med. 2005;33:2772-2777.
3. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
4. Vanhorebeek I, De Vos R, Mesotten D, Wouters PJ, De Wolf-Peeters C, Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet. 2005;365:53-59.
5. Vanhorebeek I, Gunst J, Ellger B, et al. Hyperglycemic kidney damage in an animal model of prolonged critical illness. Kidney Int. 2009;76:512-520.
6. Vanhorebeek I, Ellger B, De Vos R, et al. Tissue-specific glucose toxicity induces mitochondrial damage in a burn injury model of critical illness. Crit Care Med. 2009;37:1355-1364.
7. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014;5:66-72.
8. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627-1635.
9. Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009;71:369-375.
10. Kim KH, Lee MS. FGF21 as a stress hormone: The roles of FGF21 in stress adaptation and the treatment of metabolic diseases. Diabetes Metab J. 2014;38:245-251.
11. KimHW,Lee JE, Cha JJ, et al. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology. 2013;154:3366-3376.
12. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007;148:774-781.
13. Kim KH, Jeong YT, Oh H, et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing FGF21 as a mitokine. Nat Med. 2013;19:83-92.
14. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators-A critical appraisal. Cell Metab. 2012;16:693-705.
15. Saberi F, Heyland D, Lam M, Rapson D, Jeejeebhoy K. Prevalence, incidence, and clinical resolution of insulin resistance in critically ill patients: an observational study. JPEN J Parenter Enteral Nutr. 2008;32:227-235.
16. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002;360:219-223.
17. Weekers F, Van Herck E, Coopmans W, et al. A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response. Endocrinology. 2002;143:764-774.
18. Gunst J, Derese I, Aertgeerts A, et al. Insufficient autophagy contributes to mitochondrial dysfunction, organ failure, and adverse outcome in an animal model of critical illness. Crit Care Med. 2013; 41:182-194.
19. Ellger B, Debaveye Y, Vanhorebeek I, et al. Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes. 2006;55:1096-1105.
20. Langouche L, Vanhorebeek I, Vlasselaers D, et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest. 2005;115:2277-2286.
21. Keipert S, Ost M, Johann K, et al. Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine. Am J Physiol Endocrinol Metab. 2014;306: E469-E482.
22. De Sousa-Coelho AL, Marrero PF, Haro D. Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem J. 2012;443:165-171.
23. Itoh N. FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases. Front Endocrinol (Lausanne). 2014;5:107.
24. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response byPPAR-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5:415-425.
25. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPAR and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5:426-437.
26. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010;53:934-940.
27. Ye D, Wang Y, Li H, et al. Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1-mediated antioxidant capacity in mice. Hepatology. 2014;60:977-989.
28. Domingo P, Gallego-Escuredo JM, Domingo JC, et al. SerumFGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS. 2010;24:2629-2637.
29. Laeger T, Henagan TM, Albarado DC, et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest. 2014;124:3913-3922.
30. Davis RL, Liang C, Edema-Hildebrand F, Riley C, Needham M, Sue CM. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology. 2013;81:1819-1826.
31. Vanhorebeek I, Gunst J, Derde S, et al. Insufficient activation of autophagy allows cellular damage to accumulate in critically ill patients. J Clin Endocrinol Metab. 2011;96:E633-E645.
32. Gariani K, Drifte G, Dunn-Siegrist I, Pugin J, Jornayvaz FR. Increased FGF21 plasma levels in humans with sepsis and SIRS. Endocr Connect. 2013;2:146-153.
33. Luo Y, McKeehan WL. Stressed liver and muscle call on adipocytes with FGF21. Front Endocrinol (Lausanne). 2013;4:194.
34. Feingold KR, Grunfeld C, Heuer JG, et al. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology. 2012;153:2689-2700.
35. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov. 2005;4:854-865.
36. Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40:280-293.
37. Novoa I, Zeng H, Harding HP, Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2. J Cell Biol. 2000; 153: 1011-1022.
38. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor mediates the adaptive response to fasting. J Clin Invest. 1999;103:1489-1498.
39. Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18:333-340.
40. Gälman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPAR activation in man. Cell Metab. 2008;8:169-174.